Indaptus Therapeutics is trading at $2.09 (17.2% down) today as early pre-market strength faded and Friday’s selloff extended into the new week.
- The decline appears to be driven by fragile investor sentiment and profit-taking following recent volatility, as there are no fresh company-specific news or regulatory updates to explain the move.
- The downward pressure is idiosyncratic to the company, as the broader biotechnology sector is actually trading higher today, suggesting the move is not due to sector-wide trends.